New antifungals drugs, new approaches and vaccines

Title Antifungal name Trial phase Date
Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans. P11-6 Apr 2017
Pharmacokinetics of the Novel Echinocandin, CD101, in Multiple Animal Species. Biafungin (CD101) Mar 2017
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. SCY-078 (MK-3118) Phase 2 Mar 2017
In vitro and in vivo antifungal profile of a novel and long acting inhaled azole, PC945, on Aspergillus fumigatus infection. PC945 Mar 2017
Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested Against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY (2014) Antifungal Surveillance Program. Biafungin (CD101) Feb 2017
Special Issue: Novel Antifungal Drug Discovery General articles Feb 2017
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults. Biafungin (CD101) Jan 2017
Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties. Biafungin (CD101) Jan 2017
CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis (CAMB) MAT2203 Phase 2 Dec 2016
Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) MAT2203 Phase 2 Dec 2016

Pages